Evidence map›Paper›PMID 39464892›Full record

ReviewFrontiers in immunology2024

A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.

Yi Li, Qian Shen, Lu Feng, Chuanlong Zhang, Xiaochen Jiang, Fudong Liu, Bo Pang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi Li *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Qian Shen *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Lu Feng *First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Chuanlong ZhangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaochen JiangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Fudong LiuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Bo PangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is one of the deadliest gynecological malignancies in the world and is the leading cause of cancer-related death in women. The complexity and difficult-to-treat nature of OC pose a huge challenge to the treatment of the disease, Therefore, it is critical to find green and sustainable drug treatment options. Natural drugs have wide sources, many targets, and high safety, and are currently recognized as ideal drugs for tumor treatment, has previously been found to have a good effect on controlling tumor progression and reducing the burden of metastasis. However, its clinical transformation is often hindered by structural stability, bioavailability, and bioactivity. Emerging technologies for the treatment of OC, such as photodynamic therapy, immunotherapy, targeted therapy, gene therapy, molecular therapy, and nanotherapy, are developing rapidly, particularly, nanotechnology can play a bridging role between different therapies, synergistically drive the complementary role of differentiated treatment schemes, and has a wide range of clinical application prospects. In this review, nanoscale natural drug delivery systems (NNDDS) for targeted drug delivery against OC were extensively explored. We reviewed the mechanism of action of natural drugs against OC, reviewed the morphological composition and delivery potential of drug nanocarriers based on the application of nanotechnology in the treatment of OC, and discussed the limitations of current NNDDS research. After elucidating these problems, it will provide a theoretical basis for future exploration of novel NNDDS for anti-OC therapy.

Indexed as

Ovarian NeoplasmsAnimalsAntineoplastic AgentsBiological ProductsDrug CarriersDrug Delivery SystemsFemaleHumansNanoparticle Drug Delivery SystemNanoparticlesAntineoplastic AgentsBiological ProductsDrug CarriersNanoparticle Drug Delivery Systemchemical compoundnanoparticlesnanoscale natural drug delivery systemovarian cancertargeted drug delivery

Identifiers

PMID39464892
PMCPMC11502327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.